Global Multiple Myeloma Therapy Market

Multiple Myeloma Therapy Comprehensive Study by Type (Targeted Therapy, Chemotherapy, Radiotherapy, Bone Marrow Transplant), Application (Smouldering Multiple Myeloma, Active Multiple Myeloma), End-Use (Hospital, Clinic, Speciality Center, Others) Players and Region - Global Market Outlook to 2030

Multiple Myeloma Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Multiple Myeloma Therapy
Multiple myeloma is a malignancy that develops when malignant plasma cells multiply. The immune system relies on normal plasma cells, which are present in the bone marrow. By producing antibodies that recognize and target bacteria, plasma cells aid in the battle against infection. Cancer cells accumulate in the bone marrow, crowding out healthy blood cells in multiple myeloma. These cancerous plasma cells subsequently create aberrant proteins (m protein), which can lead to malignancies, renal damage, and immune system impairment. The launch of monoclonal antibodies (mAbs) Empliciti and Darzalex will be the key drivers of growth, as they will not only provide a new therapeutic option for MM patients, but they will also lengthen the period between relapses, extending the duration of Revlimid and/or Velcade therapies. Ninlaro and Kyprolis, second-generation proteasome inhibitors, will also improve therapeutic options for these individuals. This will alter the industry and market, which is now controlled by Revlimid, an immunomodulator, and Velcade, a proteasome inhibitor.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Multiple Myeloma Therapy is a fragmented market due to the presence of less players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Multiple Myeloma Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Onyx Pharmaceuticals, Inc (United States), Janssen Biotech, Inc (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), AbbVie Inc. (United States), Novartis AG (Switzerland), Bristol-Myers Squibb Company (United States), Eagle Pharmaceuticals, Inc (United States), Mylan N.V. (United States) and Hikma Pharmaceutical Plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Apotex Inc (Canada), Alvogen (United States) and Amneal Pharmaceutical Inc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Multiple Myeloma Therapy market by Type (Targeted Therapy, Chemotherapy, Radiotherapy and Bone Marrow Transplant), Application (Smouldering Multiple Myeloma and Active Multiple Myeloma) and Region.



On the basis of geography, the market of Multiple Myeloma Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-Use, the sub-segment i.e. Hospital will boost the Multiple Myeloma Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Launch of Second-Generation Proteasome Inhibitors

Market Growth Drivers:
Increased Prevalence of Numerous Kinds of Blood cancer and Stringent Regulatory Factors

Challenges:
Limited Target Patient Population

Restraints:
High Cost of Treatment and Stringent Regulatory Factors

Opportunities:
Increasing Product Launches, Growing Research and Development Activities and Growing Drug Development Activities

Market Leaders and their expansionary development strategies
In December 2023, AstraZeneca has entered into a definitive agreement to acquired Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.
In August 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment. This EHA-ESMO Clinical Practice Guideline provides key recommendations on the management of multiple myeloma. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe.

Key Target Audience
Drug Manufacturers and Suppliers, Academic Research Institutes, Hospitals and Clinics, Research and Development (R&D) Companies and Regulatory Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Targeted Therapy
  • Chemotherapy
  • Radiotherapy
  • Bone Marrow Transplant
By Application
  • Smouldering Multiple Myeloma
  • Active Multiple Myeloma
By End-Use
  • Hospital
  • Clinic
  • Speciality Center
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Numerous Kinds of Blood cancer
      • 3.2.2. Stringent Regulatory Factors
    • 3.3. Market Challenges
      • 3.3.1. Limited Target Patient Population
    • 3.4. Market Trends
      • 3.4.1. Launch of Second-Generation Proteasome Inhibitors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiple Myeloma Therapy, by Type, Application, End-Use and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Multiple Myeloma Therapy (Value)
      • 5.2.1. Global Multiple Myeloma Therapy by: Type (Value)
        • 5.2.1.1. Targeted Therapy
        • 5.2.1.2. Chemotherapy
        • 5.2.1.3. Radiotherapy
        • 5.2.1.4. Bone Marrow Transplant
      • 5.2.2. Global Multiple Myeloma Therapy by: Application (Value)
        • 5.2.2.1. Smouldering Multiple Myeloma
        • 5.2.2.2. Active Multiple Myeloma
      • 5.2.3. Global Multiple Myeloma Therapy by: End-Use (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Speciality Center
        • 5.2.3.4. Others
      • 5.2.4. Global Multiple Myeloma Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Multiple Myeloma Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Onyx Pharmaceuticals, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Biotech, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AbbVie Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eagle Pharmaceuticals, Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hikma Pharmaceutical Plc (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Multiple Myeloma Therapy Sale, by Type, Application, End-Use and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Multiple Myeloma Therapy (Value)
      • 7.2.1. Global Multiple Myeloma Therapy by: Type (Value)
        • 7.2.1.1. Targeted Therapy
        • 7.2.1.2. Chemotherapy
        • 7.2.1.3. Radiotherapy
        • 7.2.1.4. Bone Marrow Transplant
      • 7.2.2. Global Multiple Myeloma Therapy by: Application (Value)
        • 7.2.2.1. Smouldering Multiple Myeloma
        • 7.2.2.2. Active Multiple Myeloma
      • 7.2.3. Global Multiple Myeloma Therapy by: End-Use (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Speciality Center
        • 7.2.3.4. Others
      • 7.2.4. Global Multiple Myeloma Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiple Myeloma Therapy: by Type(USD Million)
  • Table 2. Multiple Myeloma Therapy Targeted Therapy , by Region USD Million (2018-2023)
  • Table 3. Multiple Myeloma Therapy Chemotherapy , by Region USD Million (2018-2023)
  • Table 4. Multiple Myeloma Therapy Radiotherapy , by Region USD Million (2018-2023)
  • Table 5. Multiple Myeloma Therapy Bone Marrow Transplant , by Region USD Million (2018-2023)
  • Table 6. Multiple Myeloma Therapy: by Application(USD Million)
  • Table 7. Multiple Myeloma Therapy Smouldering Multiple Myeloma , by Region USD Million (2018-2023)
  • Table 8. Multiple Myeloma Therapy Active Multiple Myeloma , by Region USD Million (2018-2023)
  • Table 9. Multiple Myeloma Therapy: by End-Use(USD Million)
  • Table 10. Multiple Myeloma Therapy Hospital , by Region USD Million (2018-2023)
  • Table 11. Multiple Myeloma Therapy Clinic , by Region USD Million (2018-2023)
  • Table 12. Multiple Myeloma Therapy Speciality Center , by Region USD Million (2018-2023)
  • Table 13. Multiple Myeloma Therapy Others , by Region USD Million (2018-2023)
  • Table 14. South America Multiple Myeloma Therapy, by Country USD Million (2018-2023)
  • Table 15. South America Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 16. South America Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 17. South America Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 18. Brazil Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 19. Brazil Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 20. Brazil Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 21. Argentina Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 22. Argentina Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 23. Argentina Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 24. Rest of South America Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 27. Asia Pacific Multiple Myeloma Therapy, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 31. China Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 32. China Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 33. China Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 34. Japan Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 35. Japan Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 36. Japan Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 37. India Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 38. India Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 39. India Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 40. South Korea Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 41. South Korea Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 42. South Korea Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 43. Taiwan Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 44. Taiwan Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 45. Taiwan Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 46. Australia Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 47. Australia Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 48. Australia Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 52. Europe Multiple Myeloma Therapy, by Country USD Million (2018-2023)
  • Table 53. Europe Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 54. Europe Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 55. Europe Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 56. Germany Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 57. Germany Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 58. Germany Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 59. France Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 60. France Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 61. France Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 62. Italy Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 63. Italy Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 64. Italy Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 65. United Kingdom Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 68. Netherlands Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 69. Netherlands Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 70. Netherlands Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 71. Rest of Europe Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 74. MEA Multiple Myeloma Therapy, by Country USD Million (2018-2023)
  • Table 75. MEA Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 76. MEA Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 77. MEA Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 78. Middle East Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 79. Middle East Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 80. Middle East Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 81. Africa Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 82. Africa Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 83. Africa Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 84. North America Multiple Myeloma Therapy, by Country USD Million (2018-2023)
  • Table 85. North America Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 86. North America Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 87. North America Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 88. United States Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 89. United States Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 90. United States Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 91. Canada Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 92. Canada Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 93. Canada Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 94. Mexico Multiple Myeloma Therapy, by Type USD Million (2018-2023)
  • Table 95. Mexico Multiple Myeloma Therapy, by Application USD Million (2018-2023)
  • Table 96. Mexico Multiple Myeloma Therapy, by End-Use USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Multiple Myeloma Therapy: by Type(USD Million)
  • Table 109. Multiple Myeloma Therapy Targeted Therapy , by Region USD Million (2025-2030)
  • Table 110. Multiple Myeloma Therapy Chemotherapy , by Region USD Million (2025-2030)
  • Table 111. Multiple Myeloma Therapy Radiotherapy , by Region USD Million (2025-2030)
  • Table 112. Multiple Myeloma Therapy Bone Marrow Transplant , by Region USD Million (2025-2030)
  • Table 113. Multiple Myeloma Therapy: by Application(USD Million)
  • Table 114. Multiple Myeloma Therapy Smouldering Multiple Myeloma , by Region USD Million (2025-2030)
  • Table 115. Multiple Myeloma Therapy Active Multiple Myeloma , by Region USD Million (2025-2030)
  • Table 116. Multiple Myeloma Therapy: by End-Use(USD Million)
  • Table 117. Multiple Myeloma Therapy Hospital , by Region USD Million (2025-2030)
  • Table 118. Multiple Myeloma Therapy Clinic , by Region USD Million (2025-2030)
  • Table 119. Multiple Myeloma Therapy Speciality Center , by Region USD Million (2025-2030)
  • Table 120. Multiple Myeloma Therapy Others , by Region USD Million (2025-2030)
  • Table 121. South America Multiple Myeloma Therapy, by Country USD Million (2025-2030)
  • Table 122. South America Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 123. South America Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 124. South America Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 125. Brazil Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 126. Brazil Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 127. Brazil Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 128. Argentina Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 129. Argentina Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 130. Argentina Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 131. Rest of South America Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 134. Asia Pacific Multiple Myeloma Therapy, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 138. China Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 139. China Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 140. China Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 141. Japan Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 142. Japan Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 143. Japan Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 144. India Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 145. India Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 146. India Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 147. South Korea Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 148. South Korea Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 149. South Korea Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 150. Taiwan Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 151. Taiwan Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 152. Taiwan Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 153. Australia Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 154. Australia Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 155. Australia Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 159. Europe Multiple Myeloma Therapy, by Country USD Million (2025-2030)
  • Table 160. Europe Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 161. Europe Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 162. Europe Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 163. Germany Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 164. Germany Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 165. Germany Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 166. France Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 167. France Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 168. France Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 169. Italy Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 170. Italy Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 171. Italy Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 172. United Kingdom Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 175. Netherlands Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 176. Netherlands Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 177. Netherlands Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 178. Rest of Europe Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 181. MEA Multiple Myeloma Therapy, by Country USD Million (2025-2030)
  • Table 182. MEA Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 183. MEA Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 184. MEA Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 185. Middle East Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 186. Middle East Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 187. Middle East Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 188. Africa Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 189. Africa Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 190. Africa Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 191. North America Multiple Myeloma Therapy, by Country USD Million (2025-2030)
  • Table 192. North America Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 193. North America Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 194. North America Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 195. United States Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 196. United States Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 197. United States Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 198. Canada Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 199. Canada Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 200. Canada Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 201. Mexico Multiple Myeloma Therapy, by Type USD Million (2025-2030)
  • Table 202. Mexico Multiple Myeloma Therapy, by Application USD Million (2025-2030)
  • Table 203. Mexico Multiple Myeloma Therapy, by End-Use USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiple Myeloma Therapy: by Type USD Million (2018-2023)
  • Figure 5. Global Multiple Myeloma Therapy: by Application USD Million (2018-2023)
  • Figure 6. Global Multiple Myeloma Therapy: by End-Use USD Million (2018-2023)
  • Figure 7. South America Multiple Myeloma Therapy Share (%), by Country
  • Figure 8. Asia Pacific Multiple Myeloma Therapy Share (%), by Country
  • Figure 9. Europe Multiple Myeloma Therapy Share (%), by Country
  • Figure 10. MEA Multiple Myeloma Therapy Share (%), by Country
  • Figure 11. North America Multiple Myeloma Therapy Share (%), by Country
  • Figure 12. Global Multiple Myeloma Therapy share by Players 2023 (%)
  • Figure 13. Global Multiple Myeloma Therapy share by Players (Top 3) 2023(%)
  • Figure 14. Global Multiple Myeloma Therapy share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Onyx Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Onyx Pharmaceuticals, Inc (United States) Revenue: by Geography 2023
  • Figure 18. Janssen Biotech, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Janssen Biotech, Inc (United States) Revenue: by Geography 2023
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 26. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 32. Eagle Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eagle Pharmaceuticals, Inc (United States) Revenue: by Geography 2023
  • Figure 34. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 36. Hikma Pharmaceutical Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Hikma Pharmaceutical Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 38. Global Multiple Myeloma Therapy: by Type USD Million (2025-2030)
  • Figure 39. Global Multiple Myeloma Therapy: by Application USD Million (2025-2030)
  • Figure 40. Global Multiple Myeloma Therapy: by End-Use USD Million (2025-2030)
  • Figure 41. South America Multiple Myeloma Therapy Share (%), by Country
  • Figure 42. Asia Pacific Multiple Myeloma Therapy Share (%), by Country
  • Figure 43. Europe Multiple Myeloma Therapy Share (%), by Country
  • Figure 44. MEA Multiple Myeloma Therapy Share (%), by Country
  • Figure 45. North America Multiple Myeloma Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Onyx Pharmaceuticals, Inc (United States)
  • Janssen Biotech, Inc (United States)
  • Johnson & Johnson (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • AbbVie Inc. (United States)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (United States)
  • Eagle Pharmaceuticals, Inc (United States)
  • Mylan N.V. (United States)
  • Hikma Pharmaceutical Plc (United Kingdom)
Additional players considered in the study are as follows:
Apotex Inc (Canada) , Alvogen (United States) , Amneal Pharmaceutical Inc (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 230 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Multiple Myeloma Therapy Market Quantitative research analysis
Global Multiple Myeloma Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Onyx Pharmaceuticals, Inc (United States), Janssen Biotech, Inc (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), AbbVie Inc. (United States), Novartis AG (Switzerland), Bristol-Myers Squibb Company (United States), Eagle Pharmaceuticals, Inc (United States), Mylan N.V. (United States) and Hikma Pharmaceutical Plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Launch of Second-Generation Proteasome Inhibitors" is seen as one of major influencing trends for Multiple Myeloma Therapy Market during projected period 2023-2030.
The Multiple Myeloma Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Multiple Myeloma Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Gynecologic Cancer Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Treatment (Chemotherapy, Rad...
$ 3650
Campylobacter Diagnostics Comprehensive Study by Type (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Hospitals, Private Laboratories, Independent P...
$ 3350
Brucellosis Comprehensive Study by Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, Others), Diagnosis (Serological Tests, Molecular Techniques, Bone Marrow ...
$ 3750
Carrion's Disease Comprehensive Study by Antibiotics (Chloramphenicol, Azithromycin, Erythromycin, Ciprofloxacin, Rifampin, Macrolides), Stages (Acute Phase, Chronic Phase), End User (Hospitals, Clin...
$ 3500
Campylobacteriosis Comprehensive Study by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Onl...
$ 3750
Bronchiolitis Comprehensive Study by Type (Viral Bronchiolitis, Bronchiolitis Obliterans), Treatment (Flu Shot, Corticosteroids, Intravenous Fluid Treatment, Others), End-users (Hospitals, Clinics, O...
$ 3650